SystImmune, a clinical-stage biopharmaceutical company, and Bristol Myers Squibb, entered an exclusive license and collaboration agreement to co-develop and commercialize SystImmune’s  BL-B01D1 in the U.S. BL-B01D1 is a potentially first-in-class EGFRxHER3 bispecific antibody-drug conjugate (ADC).    SystImmune will be responsible for development, commercialization, and manufacturing in Mainland China and will be responsible for manufacturing certain drug supplies for use outside of Mainland C...